Figure 1From: Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trialStudy design. *As per center practice. C0, trough levels; CS, corticosteroids; EVR, everolimus; HCV, hepatitis C virus; LTx, liver transplantation; M, month; MELD, model of end-stage liver disease; MMF, mycophenolate mofetil; RND, randomization; TAC, tacrolimus.Back to article page